Anti-SIRPa Monoclonal Antibody BI 770371 clinical trials
Also written BI 770371.
Its developmentBy Boehringer Ingelheim, step by step4 company-led studies, furthest phase 2: when each phase was reached, its deals, target and what is ahead.- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2022
How each study uses Anti-SIRPa Monoclonal Antibody BI 770371 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- BI 770371
- 4
Studies by the year they started
4 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2022 | 2 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Anti-SIRPa Monoclonal Antibody BI 770371.
Studies
Open first, then newest update. How each study uses Anti-SIRPa Monoclonal Antibody BI 770371 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab AloneActive, not recruitingPhase 1Boehringer IngelheimNCT06806852Written as BI 770371How we know
- A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking EzabenlimabActive, not recruitingPhase 1Boehringer IngelheimNCT05068102Written as BI 770371How we know
- A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are ToleratedActive, not recruitingPhase 1Boehringer IngelheimNCT05327946Written as BI 770371How we know
- A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASHCompletedPhase 2Boehringer IngelheimNCT06675929Written as BI 770371How we know